Agavni Mesropian

5PUBLICATIONS
46CO-AUTHORS
Molecular targetsHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Feb 02, 2026
Mutational scanning reveals oncogenic CTNNB1 mutations have diverse effects on signaling.

Anagha Krishna, Alison Meynert, Karamjit Singh Dolt

|Dec 08, 2025
Effective therapeutic targeting of CTNNB1-mutant hepatoblastoma with WNTinib.

Ugne Balaseviciute, Júlia Huguet-Pradell, Jordi Abril-Fornaguera

|Sep 23, 2025
E7386 Enhances Lenvatinib's Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma.

Agavni Mesropian, Albert Gris-Oliver, Ugne Balaseviciute

|Mar 18, 2022
Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma.

Roger Esteban-Fabró, Catherine E Willoughby, Marta Piqué-Gili

|Jun 22, 2021
Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma.

Laura Torrens, Carla Montironi, Marc Puigvehí

Pageof 1

Frequent Collaborators

4 joint publications

Jordi Abril-Fornaguera

4 joint publications

Josep M Llovet

3 joint publications

Carla Montironi

3 joint publications

Albert Gris-Oliver